Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
Phase 3
Completed
- Conditions
- Asthma
- Registration Number
- NCT00319306
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
- Aged over 18
- Confirmed diagnosis of mild to moderate asthma by doctor
- Currently receiving inhaled corticoid-steroid medicine for treatment of asthma and requiring a review of current asthma treatment
Read More
Exclusion Criteria
- Women who are pregnant, breast-feeding, or planning pregnancy
- Patients with a history of chronic obstructive pulmonary disease
- Patients using any beta blocker therapy
- Patients receiving steroid tablets or steroid injections
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method In a real life setting, to compare Symbicort® Single Inhaler Therapy with a patient's previous therapy (including low dose ICS), by assessment of the changes in the Asthma Control Questionnaire score in uncontrolled asthmatic patients.
- Secondary Outcome Measures
Name Time Method Patient Reported Outcomes: AQLQ(S), SATQ, RCP-3 scores Change in forced expiratory volume in one second (FEV1) Change in peak expiratory flow (PEF)
Trial Locations
- Locations (1)
Research Site
🇬🇧Yaxley, United Kingdom